Vildagliptin is a DPP-4 inhibitor administered twice daily. Weight neutral with low hypoglycaemia risk.
Also known as: Galvus
Inhibits DPP-4, increasing incretins. Reversible activity (unlike sitagliptin).
Reversibly blocks DPP-4, increasing GLP-1 and GIP. Reversible binding allows residual activity even at low drug levels.
Oral bioavailability: 85%. Food does not significantly affect absorption. Tmax: 1-2 hours.
Hydrolytically metabolised by peptidase in erythrocytes (inactive Ba41-795L metabolite). Does not interfere with CYP.
~2 hours (vildagliptin); ~3 hours (Ba41-795L). Elimination: ~70% urine (metabolites).
No documented drug–drug interactions for this medicine.
No documented food or drink interactions.
No documented disease interactions.
No documented pregnancy or breastfeeding information.
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
